In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Ameren’s current price exceeds its PERT-weighted fair value by 36.2%, indicating overvaluation despite high confidence in this estimate. Valuation methods show wide dispersion, with DCF suggesting negative values and EV/EBITDA much higher, reflecting fundamental uncertainty. Financial health scores reveal fair liquidity and leverage but weak growth, elevating risk amid mixed valuation signals.